A Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC). (6th November 2014) - Steinberg, Gary D; Shore, Neal; Karsh, Lawrence; Bailen, James; Woods, Michael; Schoenberg, Mark; Schreiber, Taylor H; Price, Melissa